ArticleJournal of translational medicine2013

PTPRO promoter methylation is predictive of poorer outcome for HER2-positive breast cancer: indication for personalized therapy.

Yi-Teng Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.